Ajinomoto to acquire Forge Biologics for $620m to enhance genetic medicine capabilities
Ajinomoto Co., Inc., a prominent player in the biotechnology industry, has entered into a definitive agreement to acquire Forge Biologics, a leading genetic medicines manufacturer, in a significant all-cash deal valued at $620 million. Strategic Significance of the Acquisition Forge Biologics, a viral vector and plasmid contract development and manufacturing organization (CDMO) and clinical-stage therapeutics […]